

## ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB

**The annual general meeting of Newbury Pharmaceuticals was held on Wednesday, 15 January 2025. At the meeting 10 134 809 shares were represented, which corresponds to approx. 42 percent of the total number of shares. The summary below shows the resolutions adopted at the AGM. The resolutions were adopted unanimously.**

### **Allocation of the company's result**

The AGM resolved to adopt the income statement and balance sheet for the company as well as the consolidated income statement and consolidated balance sheet for the previous financial year. The board of directors and the managing director were discharged from liability for the same period.

The AGM approved the board's proposal that the result should be carried forward.

### **Fees to the board members and the auditors**

The AGM agreed on the following fees to the board and the auditors.

Each one of the board members elected by the AGM (and who are not employed in the group) – 60,000 SEK

Fees to the auditors shall be paid in accordance with approved invoices.

### **Board members, chairman of the board and auditors**

Karl Karlsson, Andreas Hedskog, Anil Okay, Johan Strömqvist, Ramon Vila and Ivailo S. Georgiev were re-elected as board members. Karl Karlsson was re-elected as chairman of the board.

Ernst & Young AB was elected as the company's auditor, with Martin Henriksson as auditor in charge.

### **Authorization for the board to decide on issue of new shares**

The AGM resolved to authorize the board of Newbury Pharmaceuticals AB to decide to issue new shares in the company, in accordance with the board's proposal.

### **For more information, contact:**

---

Lars Minor, CEO  
[lars.minor@newburypharma.com](mailto:lars.minor@newburypharma.com)  
Mobile: +46 72-377 3005

[www.newburypharma.com](http://www.newburypharma.com)

Press Release  
15 January 2025 11:23:00 CET



## About Newbury Pharmaceuticals

---

Newbury Pharmaceuticals is building a pipeline of proprietary and licensed products with focus on specialty and branded products in the Nordics. Newbury aims to make a difference by offering treatment solutions within areas like oncology, rare diseases and neurology. The portfolio is built by leveraging experience and extensive international network. Newbury offers strategic partnerships of innovation for the benefit of the Nordic healthcare market.

Västra Hamnen Corporate Finance is the Company's Certified Adviser on Nasdaq First North and can be reached at [ca@vhcorp.se](mailto:ca@vhcorp.se) or +46 (0) 40 200 250.

## Attachments

---

[ANNUAL GENERAL MEETING OF SHAREHOLDERS IN NEWBURY PHARMACEUTICALS AB](#)